[ibd-display-video id=2385970 width=50 float=left autostart=true] IBD's unique RS Rating identifies technical performance by using a 1 (worst) to 99 (best) score that shows how a stock's price performance over the last 52 weeks matched up against all other stocks.
Decades of market research reveals that the market's biggest winners typically have an RS Rating of over 80 as they launch their biggest price moves. See if Athenahealth can continue to show renewed price strength and hit that benchmark.
Athenahealth is working on a consolidation with a 158.76 buy point . See if it can break out in volume at least 40% above average.
The company posted -7% earnings growth last quarter. Revenue increased 10%. The company is expected to report its latest numbers on or around Feb. 2.
The company holds the No. 4 rank among its peers in the Computer Software-Medical industry group. Simulations Plus ( SLP ) is the top-ranked stock within the group.